Baird on Regenxbio Inc. (RGNX): 'Incrementally negative on program update'

January 29, 2026 4:26 AM EST Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $39.00 price target on Regenxbio Inc. (NASDAQ: RGNX)The analyst comments "Incrementally ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login